BION-1301 is under clinical development by Chinook Therapeutics and currently in Phase II for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase II drugs for IgA Nephropathy (Berger’s Disease) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BION-1301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BION-1301 overview

BION-1301 is under development for the treatment of IgA nephropathy. It comprises of humanized IgG4 monoclonal antibody. The drug candidate targets APRIL-dependent survival in B-cell malignancies. The drug candidate is developed based on B-select antibody platform (B-select) technology. It is administered by intravenous and subcutaneous route. It was also under development for the treatment of  B-cell chronic lymphocytic lymphoma, colorectal cancer and relapsed or refractory multiple myeloma.

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

For a complete picture of BION-1301’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.